<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5501546</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0180365</article-id><article-id pub-id-type="publisher-id">PONE-D-17-08917</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Loci</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Glycobiology</subject><subj-group><subject>Glycoproteins</subject><subj-group><subject>Fibrinogen</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Genome-Wide Association Studies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Genome-Wide Association Studies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject><subj-group><subject>Genome-Wide Association Studies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Coronary Heart Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Coronary Heart Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Inflammatory Diseases</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Coronary artery disease-associated genetic variants and biomarkers of inflammation </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Coronary artery disease-associated genetic variants and biomarkers of inflammation</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3894-888X</contrib-id><name><surname>Christiansen</surname><given-names>Morten Krogh</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Larsen</surname><given-names>Sanne Bøjet</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nyegaard</surname><given-names>Mette</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Neergaard-Petersen</surname><given-names>Søs</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ajjan</surname><given-names>Ramzi</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Würtz</surname><given-names>Morten</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grove</surname><given-names>Erik Lerkevang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hvas</surname><given-names>Anne-Mette</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jensen</surname><given-names>Henrik Kjærulf</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kristensen</surname><given-names>Steen Dalby</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Faculty of Health, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Biomedicine, Aarhus University, Aarhus, Denmark</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, United Kingdom</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Lin</surname><given-names>Ying-Ju</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>China Medical University, TAIWAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: HKJ has received an unrestricted research grant from Pfizer, which was partly used to finance a minor part of the genetic analysis. </plain></SENT>
<SENT sid="2" pm="."><plain>This does not alter our adherence to PLOS ONE policies on sharing data and materials. </plain></SENT>
<SENT sid="3" pm="."><plain>All other authors report no competing interests. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="4" pm="."><plain>Conceptualization: MKC HKJ SDK.Formal analysis: MKC.Funding acquisition: HKJ SDK.Investigation: MKC SBL MN SNP RA MW ELG AMH SDK.Writing – original draft: MKC.Writing – review &amp; editing: SBL MN SNP RA MW ELG AMH HKJ SDK. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>mkc@dadlnet.dk</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>7</issue><elocation-id>e0180365</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Christiansen et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Christiansen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0180365.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="5" pm="."><plain>Introduction </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Genetic constitution and inflammation both contribute to development of coronary artery disease (CAD). </plain></SENT>
<SENT sid="7" pm="."><plain>Several CAD-associated single-nucleotide polymorphisms (SNPs) have recently been identified, but their functions are largely unknown. </plain></SENT>
<SENT sid="8" pm="."><plain>We investigated the associations between CAD-associated SNPs and five CAD-related inflammatory biomarkers. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="9" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>We genotyped 45 CAD-associated SNPs in 701 stable CAD patients in whom levels of high-sensitivity C-reactive protein (hsRCP), interleukin-6, calprotectin, fibrinogen and complement component 3 levels had previously been measured. </plain></SENT>
<SENT sid="11" pm="."><plain>A genetic risk score was calculated to assess the combined risk associated with all the genetic variants. </plain></SENT>
<SENT sid="12" pm="."><plain>A multiple linear regression model was used to assess associations between the genetic risk score, single SNPs, and the five inflammatory biomarkers. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="13" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>The minor allele (G) (CAD risk allele) of rs2075650 (TOMM40/APOE) was associated with lower levels of high-sensitivity C-reactive protein (effect per risk allele: -0.37 mg/l [95%CI -0.56 to -0.18 mg/l]). </plain></SENT>
<SENT sid="15" pm="."><plain>The inflammatory markers tested showed no association with the remaining 44 SNPs or with the genetic risk score. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="16" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>In stable CAD patients, the risk allele of a common CAD-associated marker at the TOMM40/APOE locus was associated with lower hsCRP levels. </plain></SENT>
<SENT sid="18" pm="."><plain>No other genetic variants or the combined effect of all variants were associated with the five inflammatory biomarkers. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Novo Nordisk (DK)</institution></funding-source><award-id>NNF14OC0008817</award-id><principal-award-recipient><name><surname>Kristensen</surname><given-names>Steen Dalby</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008648</institution-id><institution>Pfizer Foundation</institution></institution-wrap></funding-source><award-id>WS2632086</award-id><principal-award-recipient><name><surname>Jensen</surname><given-names>Henrik Kjærulf</given-names></name></principal-award-recipient></award-group><funding-statement>Funding was received from the Novo Nordic Foundation (grant no. NNF14OC0008817 to SDK) and Pfizer (unrestricted research grant no. WS2632086 to HKJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="19" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>Inflammation is of major importance for the development of coronary artery disease (CAD) [1]. </plain></SENT>
<SENT sid="21" pm="."><plain>Inflammatory cells and signaling molecules contribute to the disease process by modulating the arterial wall, promoting lipoprotein retention, plaque formation and possibly destabilization [1]. </plain></SENT>
<SENT sid="22" pm="."><plain>Accordingly, several inflammatory biomarkers have been shown to predict cardiovascular outcome [2–5]. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Over the past 10 years, large-scale genome-wide association studies (GWAS) have identified a large number of single-nucleotide polymorphisms (SNPs) associated with CAD [6]. </plain></SENT>
<SENT sid="24" pm="."><plain>Combined into genetic risk scores (GRS), these SNPs predict adverse cardiovascular events in various populations with and without prior cardiovascular disease [7–10]. </plain></SENT>
<SENT sid="25" pm="."><plain>Although the majority of loci identified seem to act through induction of atherosclerosis, little is known about the underlying mechanisms. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>The majority of CAD-associated SNPs are located in non-coding regions of the genome. </plain></SENT>
<SENT sid="27" pm="."><plain>Expression quantitative trait loci (eQTL) data indicate that the loci primarily exert their effect through regulation of nearby gene expression, but a large proportion of these genes have not previously been linked to CAD or risk factors for CAD [11,12]. </plain></SENT>
<SENT sid="28" pm="."><plain>A functional network analysis performed by the CARDIoGRAMplusC4D Consortium (as part of the largest GWAS meta-analysis available at the time of initiation of our study) suggested that SNPs related to the APOA1, IL6R, MRAS, and PLG genes may act on CAD development by affecting pathways of acute phase response signaling [11]. </plain></SENT>
<SENT sid="29" pm="."><plain>However, it remains unknown whether these SNPs are associated with commonly used outcome-associated biomarkers of inflammation such as high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), calprotectin, fibrinogen, and complement component 3 (C3) [2–5]. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Therefore, our primary aim was to investigate the association between APOA1-, IL6R-, MRAS-, and PLG-linked SNPs, and hs-CRP, IL-6, calprotectin, fibrinogen, and C3. </plain></SENT>
<SENT sid="31" pm="."><plain>Secondarily, we explored the individual associations of other CAD-associated risk SNPs and the effect of all SNPs combined using a genetic risk score (GRS). </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="32" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="33" pm="."><plain>Design and study population </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>This was a cross-sectional study including patients with stable CAD. </plain></SENT>
<SENT sid="35" pm="."><plain>The entire cohort has previously been described in detail [13]. </plain></SENT>
<SENT sid="36" pm="."><plain>Briefly, 900 patients were recruited from the Western Denmark Heart Registry between November 2007 and January 2011, and all patients had CAD as verified by coronary angiography. </plain></SENT>
<SENT sid="37" pm="."><plain>At the time of enrollment, where blood samples were obtained, patients were considered stable (i.e. no cardiovascular events or revascularization procedures within the last 12 months). </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>From the entire cohort, substudies on inflammatory biomarkers were performed comprising hs-CRP [14], IL-6 [14], calprotectin [14], fibrinogen [15,16], and C3 [15,16]. </plain></SENT>
<SENT sid="39" pm="."><plain>Patients included in these substudies were younger, more often had diabetes, prior MI and prior coronary revascularization, whereas renal failure and antihypertensive medication was less common, compared with patients not included. </plain></SENT>
<SENT sid="40" pm="."><plain>In total, one or more inflammatory markers were measured in 713 patients, and DNA was available in 704 patients. </plain></SENT>
<SENT sid="41" pm="."><plain>All patients provided informed written consent. </plain></SENT>
<SENT sid="42" pm="."><plain>The project was approved by The Central Denmark Region Committees on Health Research Ethics (record number: 1-10-72-210-15) and by the Danish Data Protection Agency (record number: 1-16-02-400-15). </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="43" pm="."><plain>Inflammatory marker measurements </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Standardized blood sampling was performed in the outpatient clinic between 8 a.m. and 3 p.m. </plain></SENT>
<SENT sid="45" pm="."><plain>Blood was sampled from the antecubital vein with patients in supine position after 30 minutes of rest using vacuum tubes, a large bore needle (19 G), and a minimum of stasis [13]. </plain></SENT>
<SENT sid="46" pm="."><plain>Blood for hs-CRP analysis was analysed using the KoneLab 30i (ILS Laboratories Scandinavia, Allerød, Denmark). </plain></SENT>
<SENT sid="47" pm="."><plain>The measurement range for hs-CRP was 0.2–10.0 mg/l. </plain></SENT>
<SENT sid="48" pm="."><plain>In 27 patients, hs-CRP values were outside this range (maximum CRP-value of 35.8 mg/l). </plain></SENT>
<SENT sid="49" pm="."><plain>These patients were excluded in order to avoid bias from patients with subclinical infections which could potentially affect the levels of the inflammatory markers measured. </plain></SENT>
<SENT sid="50" pm="."><plain>IL-6 analyses were performed using the Cobas® 6000 analyser, E module (Roche, Mannheim, Germany). </plain></SENT>
<SENT sid="51" pm="."><plain>Serum calprotectin was measured using enzyme-linked immunosorbent assay (ELISA) (MRP 8/14 Calprotectin, Bühlmann, Schönenbuch, Switzerland). </plain></SENT>
<SENT sid="52" pm="."><plain>Fibrinogen was measured by the clotting method of Clauss using a KC 10TM coagulometer (Henrich Amelung GmbH, Lemgo, Germany). </plain></SENT>
<SENT sid="53" pm="."><plain>Complement C3 was determined by ELISA according to the manufacturer’s instructions (GenWay Biotech, Inc., San Diego, CA, USA). </plain></SENT>
<SENT sid="54" pm="."><plain>The coefficient of variance was &lt;5% for both calprotectin and C3 ELISA assays. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="55" pm="."><plain>SNP selection and genotyping </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>A thorough literature review of CAD risk loci was used to select the lead SNPs or relevant proxies of 46 loci genome-wide significantly associated with CAD and/or myocardial infarction (MI) in populations of European ancestry [6]. </plain></SENT>
<SENT sid="57" pm="."><plain>This included CAD-associated lead SNPs previously linked to the APOA1, IL6R, MRAS, and PLG genes by either eQTL data or physical proximity [11]. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>DNA was obtained from whole blood and direct genotyping was performed on a Fluidigm Biomark HD as previously described [17]. </plain></SENT>
<SENT sid="59" pm="."><plain>One SNP (rs17114036) failed on all chips and three samples with less than 50% of SNPs successfully genotyped were excluded. </plain></SENT>
<SENT sid="60" pm="."><plain>Therefore, the final dataset consisted of 45 SNPs in 701 patients. </plain></SENT>
<SENT sid="61" pm="."><plain>Overall call rate was excellent (31376/31545 = 99.5%) and consistent for all SNPs, except for rs964184 (call rate: 570/701 = 81.3%). </plain></SENT>
<SENT sid="62" pm="."><plain>All genotypes were successfully called in 559/701 = 79.7% of samples, whereas ≥43 SNPs where successfully called in 697/701 = 99.4% of samples. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="63" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>Patient characteristics are reported as mean ± standard deviation (SD), median (interquartile range [IQR]) or numbers (percentage). </plain></SENT>
<SENT sid="65" pm="."><plain>Each SNP was coded as 0, 1, or 2 depending on the number of CAD risk alleles in the patient. </plain></SENT>
<SENT sid="66" pm="."><plain>Under the assumption of additive genetic effects, a multivariable linear regression model was used to test the association between the individual SNPs and hs-CRP, IL-6, calprotectin, fibrinogen, and C3, respectively. </plain></SENT>
<SENT sid="67" pm="."><plain>Predefined covariates (age, sex, diabetes, prior MI, current smoking, body mass index [BMI], and renal failure defined as estimated glomerular filtration rate ≤60 ml/min) were simultaneously added to the model. </plain></SENT>
<SENT sid="68" pm="."><plain>Therefore, the beta coefficient of a SNP corresponds to the adjusted average effect per risk allele on the inflammatory biomarker. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>To test the combined effect of all CAD-associated SNPs a weighted GRS was calculated as previously reported [17]. </plain></SENT>
<SENT sid="70" pm="."><plain>The GRS was calculated as the sum of the number of risk alleles in each individual, weighted by the log of the odds ratio for CAD obtained from the original discovery GWAS papers. </plain></SENT>
<SENT sid="71" pm="."><plain>In the rare case of a missing genotype, the average of the cohort (a number of 0–2) for that SNP was used to calculate the GRS (in order to avoid a value of zero). </plain></SENT>
<SENT sid="72" pm="."><plain>For statistical analyses, GRS was standardized meaning that the beta coefficient of the GRS corresponds to the adjusted effect on the inflammatory marker per SD increase in GRS. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>In the primary analyses, we considered a conservative Bonferroni-corrected p-value &lt;0.0025 as statistically significant (threshold: p = 0.05 / [4 SNPs × 5 inflammatory biomarkers]). </plain></SENT>
<SENT sid="74" pm="."><plain>When evaluating the remaining CAD-associated SNPs and the GRS, the level of significance was adjusted accordingly (threshold: p = 0.05 / [46 × 5] = 2.2×10−4). </plain></SENT>
<SENT sid="75" pm="."><plain>All analyses were performed using STATA version 13.1 (StataCorp, 4905 Lakeway Dr, College Station, TX, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec011"><title><text><SENT sid="76" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec012"><title><text><SENT sid="77" pm="."><plain>Patient characteristics </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>A total of 701 patients were included in data analyses. </plain></SENT>
<SENT sid="79" pm="."><plain>Patient characteristics and numbers included in each analysis are displayed in Table 1. </plain></SENT>
<SENT sid="80" pm="."><plain>Mean age was 64 ± 9 years (range: 32–85 years) and 558 (80%) were males. </plain></SENT>
<SENT sid="81" pm="."><plain>Prior MI, diabetes and renal failure were present in 627 (89%), 218 (31%), and 102 (15%) of the patients, respectively. </plain></SENT>
</text></p><SecTag type="TABLE"></SecTag></sec><sec id="sec015"><title><text><SENT sid="906" pm="."><plain>GRS and inflammatory proteins </plain></SENT>
</text></title><p><text><SENT sid="907" pm="."><plain>We found no associations between the GRS and hs-CRP, IL-6, calprotectin, fibrinogen, or C3 with results detailed in Fig 3. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0180365.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180365.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="908" pm="."><plain>Scatterplots of the association between inflammatory markers and the standardized GRS. </plain></SENT>
</text></title><p><text><SENT sid="909" pm="."><plain>Abbreviations: GRS, genetic risk score; hs-CRP, high-sensitivity C-reactive protein. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0180365.g003"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec016"><title><text><SENT sid="910" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="911" pm="."><plain>In the present study of patients with established CAD, we investigated the association between 45 lead SNPs from loci associated with CAD and five common biochemical markers of inflammation. </plain></SENT>
<SENT sid="912" pm="."><plain>The main findings were; 1) for SNP rs2075650 in the TOMM40, APOE locus, the established CAD-risk allele was significantly associated with lower hs-CRP levels, 2) No other CAD-related SNPs were associated with the inflammatory marker levels, either measured as individual SNPs or when combined into a GRS. </plain></SENT>
</text></p><p><text><SENT sid="913" pm="."><plain>Previous GWASs have demonstrated a robust association between the rs2075650 G-allele and an increased risk of CAD [11]. </plain></SENT>
<SENT sid="914" pm="."><plain>In a recent study based on the present cohort, subanalysis also confirmed an association between rs2075650 and recurrent CAD events showing that an increase in the number of CAD risk alleles was associated with a hazard ratio of 1.40 (95% CI 1.00–1.97) of the primary endpoint composed of cardiovascular death, myocardial infarction and stable coronary revascularization [19]. </plain></SENT>
<SENT sid="915" pm="."><plain>Considering the well-established relationship between increasing levels of hs-CRP and adverse cardiovascular outcome [20], it may be surprising that the CAD risk allele of rs2075650 was associated with lower levels of hs-CRP in our sample. </plain></SENT>
<SENT sid="916" pm="."><plain>However, our findings are consistent with results from several previous large population-based cohort studies. </plain></SENT>
<SENT sid="917" pm="."><plain>In these studies, the same inverse relationship between the CAD risk allele and lower levels of hs-CRP has also been observed in European Americans [21], Australian twin families [22], Asians [23], and Hispanics [21] but not Afro-Americans [21]. </plain></SENT>
<SENT sid="918" pm="."><plain>Our work extends these findings by demonstrating an association in patients with established CAD. </plain></SENT>
<SENT sid="919" pm="."><plain>The mechanistic explanation for this inverse association is currently unknown. </plain></SENT>
<SENT sid="920" pm="."><plain>The marker rs2075650 is located in the TOMM40 gene, just upstream of APOE, and APOC1. </plain></SENT>
<SENT sid="921" pm="."><plain>The CAD risk allele (G) has been associated with a range of other phenotypes including reduced longevity [24], reduced BMI [25], increased low-density lipoprotein cholesterol (LDL-C) [22,26], and an increased risk of Alzheimer’s disease [27]. </plain></SENT>
<SENT sid="922" pm="."><plain>Because of the relatively strong linkage disequilibrium in the TOMM40/APOE locus, it has been suggested that the G-allele at rs2075650 is in fact tagging causal variation in the APOE gene. </plain></SENT>
<SENT sid="923" pm="."><plain>The APOE encodes the apolipoprotein E with three different isoforms (ε2, ε3, and ε4 defined by the combination of rs7412 and rs429358. </plain></SENT>
<SENT sid="924" pm="."><plain>Northwestern European ancestry (CEU): r2 = 0.02 and r2 = 0.20 with rs2075650, respectively), of which the ε4 isoform has long been known to associate with LDL-C, Alzheimer’s disease, and hs-CRP [28,29]. </plain></SENT>
<SENT sid="925" pm="."><plain>However, recent data suggest that the TOMM40/APOE locus is genetically complex [30], and therefore it is plausible that the G-allele is tagging different underlying causal variants with different effects on CAD risk and hs-CRP, a concept supported by Middleberg et al [22]. </plain></SENT>
<SENT sid="926" pm="."><plain>This would also be in line with the current understanding that hs-CRP is not causally related to cardiovascular risk [31]. </plain></SENT>
</text></p><p><text><SENT sid="927" pm="."><plain>Some previous GWASs have explored the association between CAD-associated risk variants and common inflammatory markers, of which the IL6R locus has been associated with several. </plain></SENT>
<SENT sid="928" pm="."><plain>In studies of hs-CRP, the IL6R locus (rs4129267) was consistently, though moderately, associated with hs-CRP levels (CEU: r2 = 0.54 with rs4845625) [32–34]. </plain></SENT>
<SENT sid="929" pm="."><plain>Furthermore, IL6R (rs4129267) has been associated with plasma levels of fibrinogen and IL-6 [35–37]. </plain></SENT>
<SENT sid="930" pm="."><plain>Although we observed a nominal association between the IL6R locus and C3, our study does not support a significant effect of IL6R on the inflammatory response. </plain></SENT>
<SENT sid="931" pm="."><plain>Other CAD-associated loci have also emerged in GWASs of inflammatory markers. </plain></SENT>
<SENT sid="932" pm="."><plain>A large study from the CHARGE (Cohorts for Heart and Aging Research in Genetic Epidemiology) consortium demonstrated a significant association between fibrinogen and variants near LIPA (rs2250644) and SH2B3 (rs7310615) [36]. </plain></SENT>
<SENT sid="933" pm="."><plain>Although these variants are in perfect linkage disequilibrium with the SNPs genotyped in our study (CEU: r2 = 1.00 for both), we did not find evidence of such association. </plain></SENT>
<SENT sid="934" pm="."><plain>Other GWASs have also demonstrated weak associations between variants at the AB0 locus (rs657152 and rs8176704; CEU: r2 = 0.46 and r2 = 0.02 with rs495828) and IL-6 [34,37], and a Chinese GWAS of C3 found an association with rs11575839 close to HLA-C (CEU: r2 = 0.02 with rs3869109) [38]. </plain></SENT>
<SENT sid="935" pm="."><plain>We were not able to confirm any of these associations. </plain></SENT>
<SENT sid="936" pm="."><plain>Importantly, our study was not powered to detect very small effect sizes. </plain></SENT>
<SENT sid="937" pm="."><plain>However, it is striking that none of our estimates indicated even a trend towards such relationships. </plain></SENT>
<SENT sid="938" pm="."><plain>Several explanations for these inconsistencies may exist. </plain></SENT>
<SENT sid="939" pm="."><plain>Some of the SNPs tagged in prior GWASs display different allele frequencies compared with the CAD-associated lead SNPs genotyped in our study and slightly different ancestral origins may possibly play a role as well. </plain></SENT>
<SENT sid="940" pm="."><plain>However, another important explanation may relate to the fact that we included patients with established CAD in contrast to prior studies performed in population-based cohorts without known cardiovascular disease. </plain></SENT>
<SENT sid="941" pm="."><plain>Patients with CAD have an increased inflammatory response compared with healthy subjects [2], either as the cause or as a consequence of CAD. </plain></SENT>
<SENT sid="942" pm="."><plain>Therefore, causal genetic variants might not associate with the levels of inflammatory biomarkers in cohorts where all patients are affected by CAD, although such an association may be evident in community-based populations, where some patients likely have subclinical CAD. </plain></SENT>
<SENT sid="943" pm="."><plain>In this context, it is important to note that we included stable CAD patients in our study. </plain></SENT>
<SENT sid="944" pm="."><plain>Ninety percent had previous MI occurring at least 12 months prior to inclusion, thus making it less likely that prior MIs influenced the levels of inflammatory biomarkers. </plain></SENT>
</text></p><p><text><SENT sid="945" pm="."><plain>Calprotectin is suggested a new biomarker of CAD [39–41]. </plain></SENT>
<SENT sid="946" pm="."><plain>The expression of calprotectin has been found at the site of plaque rupture and in macrophages of atherosclerotic plaques and is considered an inflammatory marker of plaque instability [40,42]. </plain></SENT>
<SENT sid="947" pm="."><plain>To our knowledge, the present study is the first to explore the association between calprotectin and CAD-associated risk variants. </plain></SENT>
<SENT sid="948" pm="."><plain>Although none of the CAD-associated variants significantly affected calprotectin levels, a trend was observed for rs1561198. </plain></SENT>
<SENT sid="949" pm="."><plain>This SNP is located between the VAMP5 and VAMP8 genes, whose products are involved in different aspects of vesicle trafficking including cytokine release and phagocytosis [43]. </plain></SENT>
<SENT sid="950" pm="."><plain>Hence, a link between this locus and calprotectin levels may plausibly exist. </plain></SENT>
<SENT sid="951" pm="."><plain>However, further studies with larger number of individuals are needed to confirm this hypothesis. </plain></SENT>
</text></p><p><text><SENT sid="952" pm="."><plain>Our study has limitations. </plain></SENT>
<SENT sid="953" pm="."><plain>Because of the number of statistical tests performed, we applied a conservative Bonferroni-corrected threshold of significance to reduce the risk of type I errors. </plain></SENT>
<SENT sid="954" pm="."><plain>This, together with the moderate sample size in the context of common complex diseases, reduces the power to detect small effect sizes, in particular for SNPs with low minor allele frequencies and for hs-CRP, IL-6, and calprotectin, which were not assessed in all patients. </plain></SENT>
<SENT sid="955" pm="."><plain>Therefore, our study should be considered as exploratory. </plain></SENT>
<SENT sid="956" pm="."><plain>We did not assess the presence of other inflammatory conditions, which may also affect the levels of inflammatory biomarkers. </plain></SENT>
<SENT sid="957" pm="."><plain>In case of bias, this would likely lead the associations towards the null, since no strong association between the genotyped SNPs and any such conditions has been reported. </plain></SENT>
<SENT sid="958" pm="."><plain>Moreover, we performed the statistical analyses assuming additive genetic effects of the risk alleles. </plain></SENT>
<SENT sid="959" pm="."><plain>Although this assumption may be reasonable for most of the genetic loci investigated, some might better fit a recessive model [44], which would affect the power of our analyses. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions" id="sec017"><title><text><SENT sid="960" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="961" pm="."><plain>In the present study, a common CAD-associated variant at the TOMM40/APOE locus (rs2075650) was significantly associated with lower levels of hs-CRP in patients with stable CAD. </plain></SENT>
<SENT sid="962" pm="."><plain>Future studies using deep sequencing of the TOMM40/APOE locus in large clinical samples are warranted to determine if rs2075650 is truly causing opposite allelic effects on CAD and hs-CRP, or if the opposite association is explained by underlying linkage disequilibrium with several hidden functional variants of which some affect the development of CAD independent of hs-CRP. </plain></SENT>
<SENT sid="963" pm="."><plain>None of the remaining variants, both assessed independently or combined as a GRS, were associated with hs-CRP, IL-6, calprotectin, fibrinogen, or C3. </plain></SENT>
<SENT sid="964" pm="."><plain>Our findings may suggest that the effect of these CAD-loci on CAD development does not act through pathways significantly affecting these commonly used inflammatory biomarkers. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec018"><title><text><SENT sid="965" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0180365.s001"><label>S1 File</label><caption><title><text><SENT sid="966" pm="."><plain>Competing interests statement. </plain></SENT>
</text></title><p><text><SENT sid="967" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0180365.s001.pdf"><caption><p><text><SENT sid="968" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0180365.s002"><label>S2 File</label><caption><title><text><SENT sid="969" pm="."><plain>Dataset file. </plain></SENT>
</text></title><p><text><SENT sid="970" pm="."><plain>(DTA) </plain></SENT>
</text></p></caption><media xlink:href="pone.0180365.s002.dta"><caption><p><text><SENT sid="971" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="972" pm="."><plain>The authors are grateful to Lise Nielsen Wulff for assisting with patient inclusion. </plain></SENT>
<SENT sid="973" pm="."><plain>We also appreciate the help from Jakob Helin and Vivi Bo Mogensen for laboratory support and from Peter Nissen for administrating the biobank. </plain></SENT>
<SENT sid="974" pm="."><plain>Funding was received from the Novo Nordic Foundation (grant no. NNF14OC0008817 to SDK) and Pfizer (unrestricted research grant no. WS2632086 to HKJ). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0180365.ref001"><text><SENT sid="975" pm="."><plain>1LibbyP, RidkerPM, HanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473: 317–325. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature10146">10.1038/nature10146</ext-link> <?supplied-pmid 21593864?>21593864 </plain></SENT>
</text></ref><ref id="pone.0180365.ref002"><text><SENT sid="976" pm="."><plain>2Emerging Risk Factors Collaboration, KaptogeS, Di AngelantonioE, PennellsL, WoodAM, WhiteIR, et al C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367: 1310–1320. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1107477">10.1056/NEJMoa1107477</ext-link> <?supplied-pmid 23034020?>23034020 </plain></SENT>
</text></ref><ref id="pone.0180365.ref003"><text><SENT sid="977" pm="."><plain>3KaptogeS, SeshasaiSRK, GaoP, FreitagDF, ButterworthAS, BorglykkeA, et al Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. European Heart Journal. 2014;35: 578–589. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/eht367">10.1093/eurheartj/eht367</ext-link> <?supplied-pmid 24026779?>24026779 </plain></SENT>
</text></ref><ref id="pone.0180365.ref004"><text><SENT sid="978" pm="."><plain>4JENSENLJN, PEDERSENS, BJERREM, MOGELVANGR, JENSENJS, FLYVBJERGA. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol. 2010;23: 123–129. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1540-8183.2010.00532.x">10.1111/j.1540-8183.2010.00532.x</ext-link> <?supplied-pmid 20337863?>20337863 </plain></SENT>
</text></ref><ref id="pone.0180365.ref005"><text><SENT sid="979" pm="."><plain>5MuscariA, BozzoliC, PudduGM, SangiorgiZ, DormiA, RovinettiC, et al Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98: 357–364. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0002-9343(99)80314-3">10.1016/S0002-9343(99)80314-3</ext-link> <?supplied-pmid 7709948?>7709948 </plain></SENT>
</text></ref><ref id="pone.0180365.ref006"><text><SENT sid="980" pm="."><plain>6McPhersonR. Genome-Wide Association Studies of Cardiovascular Disease in European and Non-European Populations. Curr Genet Med Rep. 2014;2: 1–12. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40142-014-0033-y">10.1007/s40142-014-0033-y</ext-link> </plain></SENT>
</text></ref><ref id="pone.0180365.ref007"><text><SENT sid="981" pm="."><plain>7RipattiS, TikkanenE, Orho-MelanderM, HavulinnaAS, SilanderK, SharmaA, et al A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376: 1393–1400. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(10)61267-6">10.1016/S0140-6736(10)61267-6</ext-link> <?supplied-pmid 20971364?>20971364 </plain></SENT>
</text></ref><ref id="pone.0180365.ref008"><text><SENT sid="982" pm="."><plain>8GannaA, MagnussonPKE, PedersenNL, de FaireU, ReillyM, ArnlövJ, et al Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. </plain></SENT>
<SENT sid="983" pm="."><plain>Lippincott Williams &amp; Wilkins; 2013;33: 2267–2272. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/ATVBAHA.113.301218">10.1161/ATVBAHA.113.301218</ext-link> <?supplied-pmid 23685553?>23685553 </plain></SENT>
</text></ref><ref id="pone.0180365.ref009"><text><SENT sid="984" pm="."><plain>9AbrahamG, HavulinnaAS, BhalalaOG, ByarsSG, De LiveraAM, YetukuriL, et al Genomic prediction of coronary heart disease. European Heart Journal. 2016;37: 3267–3278. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehw450">10.1093/eurheartj/ehw450</ext-link> <?supplied-pmid 27655226?>27655226 </plain></SENT>
</text></ref><ref id="pone.0180365.ref010"><text><SENT sid="985" pm="."><plain>10VaaraS, TikkanenE, ParkkonenO, LokkiM-L, RipattiS, PerolaM, et al Genetic Risk Scores Predict Recurrence of Acute Coronary Syndrome. Circulation: Cardiovascular Genetics. </plain></SENT>
<SENT sid="986" pm="."><plain>Lippincott Williams &amp; Wilkins; 2016;9: 172–178. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCGENETICS.115.001271">10.1161/CIRCGENETICS.115.001271</ext-link> <?supplied-pmid 26980882?>26980882 </plain></SENT>
</text></ref><ref id="pone.0180365.ref011"><text><SENT sid="987" pm="."><plain>11CARDIoGRAMplusC4D Consortium, DeloukasP, KanoniS, WillenborgC, FarrallM, AssimesTL, et al Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45: 25–33. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.2480">10.1038/ng.2480</ext-link> <?supplied-pmid 23202125?>23202125 </plain></SENT>
</text></ref><ref id="pone.0180365.ref012"><text><SENT sid="988" pm="."><plain>12MusunuruK, StrongA, Frank-KamenetskyM, LeeNE, AhfeldtT, SachsKV, et al From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466: 714–719. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature09266">10.1038/nature09266</ext-link> <?supplied-pmid 20686566?>20686566 </plain></SENT>
</text></ref><ref id="pone.0180365.ref013"><text><SENT sid="989" pm="."><plain>13LarsenSB, GroveEL, Neergaard-PetersenS, WürtzM, HvasA-M, KristensenSD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS ONE. 2015;10: e0126767 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0126767">10.1371/journal.pone.0126767</ext-link> <?supplied-pmid 25993271?>25993271 </plain></SENT>
</text></ref><ref id="pone.0180365.ref014"><text><SENT sid="990" pm="."><plain>14LarsenSB, GroveEL, PareekM, KristensenSD, HvasA-M. Calprotectin and platelet aggregation in patients with stable coronary artery disease. PLoS ONE. 2015;10: e0125992 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0125992">10.1371/journal.pone.0125992</ext-link> <?supplied-pmid 25970343?>25970343 </plain></SENT>
</text></ref><ref id="pone.0180365.ref015"><text><SENT sid="991" pm="."><plain>15Neergaard-PetersenS, AjjanR, HvasA-M, HessK, LarsenSB, KristensenSD, et al Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. EckleT, editor. PLoS ONE. 2013;8: e71150–8. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0071150">10.1371/journal.pone.0071150</ext-link> <?supplied-pmid 23976993?>23976993 </plain></SENT>
</text></ref><ref id="pone.0180365.ref016"><text><SENT sid="992" pm="."><plain>16Neergaard-PetersenS, HvasAM, KristensenSD, GroveEL, LarsenSB, PhoenixF, et al The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014;112: 1142–1150. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1160/TH14-05-0468">10.1160/TH14-05-0468</ext-link> <?supplied-pmid 25187394?>25187394 </plain></SENT>
</text></ref><ref id="pone.0180365.ref017"><text><SENT sid="993" pm="."><plain>17ChristiansenMK, NyegaardM, PedersenLN, LarsenSB, WürtzM, HjortJ, et al A 45-SNP genetic risk score is increased in early-onset coronary artery disease but independent of familial disease clustering. Atherosclerosis. 2017;257: 172–178. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.atherosclerosis.2017.01.010">10.1016/j.atherosclerosis.2017.01.010</ext-link> <?supplied-pmid 28142076?>28142076 </plain></SENT>
</text></ref><ref id="pone.0180365.ref018"><text><SENT sid="994" pm="."><plain>18JohnsonAD, HandsakerRE, PulitSL, NizzariMM, O’DonnellCJ, de BakkerPIW. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008;24: 2938–2939. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btn564">10.1093/bioinformatics/btn564</ext-link> <?supplied-pmid 18974171?>18974171 </plain></SENT>
</text></ref><ref id="pone.0180365.ref019"><text><SENT sid="995" pm="."><plain>19ChristiansenMK, NyegaardM, LarsenSB, GroveEL, WürtzM, Neergaard-PetersenS, et al A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease. International Journal of Cardiology. </plain></SENT>
<SENT sid="996" pm="."><plain>Elsevier Ireland Ltd; 2017;: 1–6. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2017.04.045">10.1016/j.ijcard.2017.04.045</ext-link> <?supplied-pmid 28442232?>28442232 </plain></SENT>
</text></ref><ref id="pone.0180365.ref020"><text><SENT sid="997" pm="."><plain>20Emerging Risk Factors Collaboration, KaptogeS, Di AngelantonioE, LoweG, PepysMB, ThompsonSG, et al C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375: 132–140. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(09)61717-7">10.1016/S0140-6736(09)61717-7</ext-link> <?supplied-pmid 20031199?>20031199 </plain></SENT>
</text></ref><ref id="pone.0180365.ref021"><text><SENT sid="998" pm="."><plain>21KocarnikJM, PendergrassSA, CartyCL, PankowJS, SchumacherFR, ChengI, et al Multiancestral analysis of inflammation-related genetic variants and C-reactive protein in the population architecture using genomics and epidemiology study. Circulation: Cardiovascular Genetics. </plain></SENT>
<SENT sid="999" pm="."><plain>American Heart Association, Inc; 2014;7: 178–188. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCGENETICS.113.000173">10.1161/CIRCGENETICS.113.000173</ext-link> <?supplied-pmid 24622110?>24622110 </plain></SENT>
</text></ref><ref id="pone.0180365.ref022"><text><SENT sid="1000" pm="."><plain>22MiddelbergRPS, FerreiraMAR, HendersAK, HeathAC, MaddenPAF, MontgomeryGW, et al Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med Genet. </plain></SENT>
<SENT sid="1001" pm="."><plain>BioMed Central; 2011;12: 123 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2350-12-123">10.1186/1471-2350-12-123</ext-link> <?supplied-pmid 21943158?>21943158 </plain></SENT>
</text></ref><ref id="pone.0180365.ref023"><text><SENT sid="1002" pm="."><plain>23DorajooR, LiR, IkramMK, LiuJ, FroguelP, LeeJ, et al Are C-reactive protein associated genetic variants associated with serum levels and retinal markers of microvascular pathology in Asian populations from Singapore? PLoS ONE. 2013;8: e67650 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0067650">10.1371/journal.pone.0067650</ext-link> <?supplied-pmid 23844046?>23844046 </plain></SENT>
</text></ref><ref id="pone.0180365.ref024"><text><SENT sid="1003" pm="."><plain>24DeelenJ, BeekmanM, UhH-W, HelmerQ, KuningasM, ChristiansenL, et al Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell. 2011;10: 686–698. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1474-9726.2011.00705.x">10.1111/j.1474-9726.2011.00705.x</ext-link> <?supplied-pmid 21418511?>21418511 </plain></SENT>
</text></ref><ref id="pone.0180365.ref025"><text><SENT sid="1004" pm="."><plain>25GuoY, LanktreeMB, TaylorKC, HakonarsonH, LangeLA, KeatingBJ, et al Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. Human Molecular Genetics. 2013;22: 184–201. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/dds396">10.1093/hmg/dds396</ext-link> <?supplied-pmid 23001569?>23001569 </plain></SENT>
</text></ref><ref id="pone.0180365.ref026"><text><SENT sid="1005" pm="."><plain>26SandhuMS, WaterworthDM, DebenhamSL, WheelerE, PapadakisK, ZhaoJH, et al LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008;371: 483–491. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(08)60208-1">10.1016/S0140-6736(08)60208-1</ext-link> <?supplied-pmid 18262040?>18262040 </plain></SENT>
</text></ref><ref id="pone.0180365.ref027"><text><SENT sid="1006" pm="."><plain>27DennyJC, BastaracheL, RitchieMD, CarrollRJ, ZinkR, MosleyJD, et al Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013;31: 1102–1110. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.2749">10.1038/nbt.2749</ext-link> <?supplied-pmid 24270849?>24270849 </plain></SENT>
</text></ref><ref id="pone.0180365.ref028"><text><SENT sid="1007" pm="."><plain>28CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, et al Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261: 921–923. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.8346443">10.1126/science.8346443</ext-link> <?supplied-pmid 8346443?>8346443 </plain></SENT>
</text></ref><ref id="pone.0180365.ref029"><text><SENT sid="1008" pm="."><plain>29ChasmanDI, KozlowskiP, ZeeRY, KwiatkowskiDJ, RidkerPM. Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun. 2006;7: 211–219. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.gene.6364289">10.1038/sj.gene.6364289</ext-link> <?supplied-pmid 16511556?>16511556 </plain></SENT>
</text></ref><ref id="pone.0180365.ref030"><text><SENT sid="1009" pm="."><plain>30BekrisLM, LutzF, YuC-E. Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. J Hum Genet. 2012;57: 18–25. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jhg.2011.123">10.1038/jhg.2011.123</ext-link> <?supplied-pmid 22089642?>22089642 </plain></SENT>
</text></ref><ref id="pone.0180365.ref031"><text><SENT sid="1010" pm="."><plain>31C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), WensleyF, GaoP, BurgessS, KaptogeS, Di AngelantonioE, et al Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342: d548 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.d548">10.1136/bmj.d548</ext-link> <?supplied-pmid 21325005?>21325005 </plain></SENT>
</text></ref><ref id="pone.0180365.ref032"><text><SENT sid="1011" pm="."><plain>32RidkerPM, ParéG, ParkerA, ZeeRYL, DanikJS, BuringJE, et al Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 2008;82: 1185–1192. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2008.03.015">10.1016/j.ajhg.2008.03.015</ext-link> <?supplied-pmid 18439548?>18439548 </plain></SENT>
</text></ref><ref id="pone.0180365.ref033"><text><SENT sid="1012" pm="."><plain>33DehghanA, DupuisJ, BarbalicM, BisJC, EiriksdottirG, LuC, et al Meta-analysis of genome-wide association studies in &gt;80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123: 731–738. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.110.948570">10.1161/CIRCULATIONAHA.110.948570</ext-link> <?supplied-pmid 21300955?>21300955 </plain></SENT>
</text></ref><ref id="pone.0180365.ref034"><text><SENT sid="1013" pm="."><plain>34ShahT, ZabanehD, GauntT, SwerdlowDI, ShahS, TalmudPJ, et al Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. Circulation: Cardiovascular Genetics. 2013;6: 163–170. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCGENETICS.112.964254">10.1161/CIRCGENETICS.112.964254</ext-link> <?supplied-pmid 23505291?>23505291 </plain></SENT>
</text></ref><ref id="pone.0180365.ref035"><text><SENT sid="1014" pm="."><plain>35Sabater-LlealM, HuangJ, ChasmanD, NaitzaS, DehghanA, JohnsonAD, et al Multiethnic meta-analysis of genome-wide association studies in &gt;100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation. 2013;128: 1310–1324. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.113.002251">10.1161/CIRCULATIONAHA.113.002251</ext-link> <?supplied-pmid 23969696?>23969696 </plain></SENT>
</text></ref><ref id="pone.0180365.ref036"><text><SENT sid="1015" pm="."><plain>36de VriesPS, ChasmanDI, Sabater-LlealM, ChenM-H, HuffmanJE, SteriM, et al A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics. 2016;25: 358–370. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddv454">10.1093/hmg/ddv454</ext-link> <?supplied-pmid 26561523?>26561523 </plain></SENT>
</text></ref><ref id="pone.0180365.ref037"><text><SENT sid="1016" pm="."><plain>37NaitzaS, PorcuE, SteriM, TaubDD, MulasA, XiaoX, et al A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet. 2012;8: e1002480 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pgen.1002480">10.1371/journal.pgen.1002480</ext-link> <?supplied-pmid 22291609?>22291609 </plain></SENT>
</text></ref><ref id="pone.0180365.ref038"><text><SENT sid="1017" pm="."><plain>38YangX, SunJ, GaoY, TanA, ZhangH, HuY, et al Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects. PLoS Genet. 2012;8: e1002916 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pgen.1002916">10.1371/journal.pgen.1002916</ext-link> <?supplied-pmid 23028341?>23028341 </plain></SENT>
</text></ref><ref id="pone.0180365.ref039"><text><SENT sid="1018" pm="."><plain>39HealyAM, PickardMD, PradhanAD, WangY, ChenZ, CroceK, et al Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113: 2278–2284. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.105.607333">10.1161/CIRCULATIONAHA.105.607333</ext-link> <?supplied-pmid 16682612?>16682612 </plain></SENT>
</text></ref><ref id="pone.0180365.ref040"><text><SENT sid="1019" pm="."><plain>40AltweggLA, NeidhartM, HersbergerM, MüllerS, EberliFR, CortiR, et al Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. European Heart Journal. 2007;28: 941–948. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehm078">10.1093/eurheartj/ehm078</ext-link> <?supplied-pmid 17387139?>17387139 </plain></SENT>
</text></ref><ref id="pone.0180365.ref041"><text><SENT sid="1020" pm="."><plain>41MorrowDA, WangY, CroceK, SakumaM, SabatineMS, GaoH, et al Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155: 49–55. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2007.08.018">10.1016/j.ahj.2007.08.018</ext-link> <?supplied-pmid 18082488?>18082488 </plain></SENT>
</text></ref><ref id="pone.0180365.ref042"><text><SENT sid="1021" pm="."><plain>42IonitaMG, VinkA, DijkeIE, LamanJD, PeetersW, van der KraakPH, et al High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2009;29: 1220–1227. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/ATVBAHA.109.190314">10.1161/ATVBAHA.109.190314</ext-link> <?supplied-pmid 19520974?>19520974 </plain></SENT>
</text></ref><ref id="pone.0180365.ref043"><text><SENT sid="1022" pm="."><plain>43ChaineauM, DanglotL, GalliT. Multiple roles of the vesicular-SNARE TI-VAMP in post-Golgi and endosomal trafficking. FEBS Lett. 2009;583: 3817–3826. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.febslet.2009.10.026">10.1016/j.febslet.2009.10.026</ext-link> <?supplied-pmid 19837067?>19837067 </plain></SENT>
</text></ref><ref id="pone.0180365.ref044"><text><SENT sid="1023" pm="."><plain>44SchunkertH, KönigIR, KathiresanS, ReillyMP, AssimesTL, HólmH, et al Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43: 333–338. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.784">10.1038/ng.784</ext-link> <?supplied-pmid 21378990?>21378990 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
